Profile data is unavailable for this security.
About the company
Cassava Sciences, Inc. is a biotechnology company focused on Alzheimer's disease. The Company's science is based on stabilizing, but not removing, a critical protein in the brain. The Company is focused on its product discovery and development efforts on disorders of the nervous system. Its lead therapeutic drug candidate, simufilam, is under clinical evaluation for the proposed treatment of Alzheimer's disease dementia in Phase 3 clinical studies. The Company has two biopharmaceutical assets under development. Its lead therapeutic product candidate, called simufilam, is an oral treatment for Alzheimer's disease dementia. Its lead investigational diagnostic product candidate, called SavaDx, is a way to detect the presence of Alzheimer's disease from a small sample of blood. Simufilam targets an altered form of a protein called filamin A in the Alzheimer's brain. It owns rights to its drug and diagnostic assets and related technologies, without royalty obligations to any third party.
- Revenue in USD (TTM)0.00
- Net income in USD-47.90m
- Incorporated1998
- Employees29.00
- LocationCassava Sciences Inc6801 N CAPITAL OF TEXAS HIGHWAYBUILDING 1; SUITE 300AUSTIN 78731United StatesUSA
- Phone+1 (512) 501-2444
- Fax+1 (512) 614-0414
- Websitehttps://www.cassavasciences.com/